Modality
Gene Therapy
MOA
GLP-1ag
Target
CD19
Pathway
PD-1/PD-L1
Ewing Sarcoma
Development Pipeline
Preclinical
~Aug 2011
→ ~Nov 2012
Phase 1
~Feb 2013
→ ~May 2014
Phase 2
~Aug 2014
→ ~Nov 2015
Phase 3
~Feb 2016
→ ~May 2017
NDA/BLA
~Aug 2017
→ ~Nov 2018
Approved
Feb 2019
→ Nov 2030
ApprovedCurrent
NCT08734482
1,733 pts·Ewing Sarcoma
2019-02→2030-11·Terminated
NCT08559626
1,407 pts·Ewing Sarcoma
2019-05→TBD·Terminated
3,140 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2030-11-214.6y awayPh3 Readout· Ewing Sarcoma
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Termina…
Approved
Termina…
Catalysts
Ph3 Readout
2030-11-21 · 4.6y away
Ewing Sarcoma
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08734482 | Approved | Ewing Sarcoma | Terminated | 1733 | CR |
| NCT08559626 | Approved | Ewing Sarcoma | Terminated | 1407 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| Tirarelsin | TG Therapeutics | NDA/BLA | CD19 | |
| CRS-184 | CRISPR Therapeutics | Phase 1/2 | AHR | |
| Polazanubrutinib | Tango Ther | Phase 1 | IL-17A |